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Aldosterone is implicated in the pathogenesis of several cardiovascular diseases, including 
ischemia reperfusion (I/R) and myocardial infarction, and also causes oxidative stress and 
inflammation in cardiovascular systems. Benidipine, a long-acting T- and L-type calcium channel 
blocker, reduces infarct size following myocardial I/R in rabbits. Benidipine also inhibits the 
production of aldosterone in vitro. However, the precise mechanism of this phenomenon in vivo 
remains unknown. We therefore evaluated whether benedipine has a beneficial role through the 
regulation of oxidative stress in myocardial I/R. C57BL/6J mice were subjected to 30 min of left 
ascending coronary I/R. Benidipine was administered orally at 3 mg/kg daily for 3 weeks without 
any changes in hemodynamic variables. Benidipine significantly reduced infarction size (13.4 ± 
2.5%) compared to controls (25.5 ± 3.6%). Urinary 8-hydroxy-2’ deoxyguanosine (8-OHdG), a 
marker of oxidative DNA damage, increased significantly after I/R. I/R-induced increases in 
8-OHdG were significantly lower with benidipine. Local myocardial 8-OHdG was also elevated 
in I/R, but this augmentation was significantly suppressed with benidipine. The plasma 
aldosterone concentration significantly increased 2 days after I/R and remained elevated at least 7 
days after I/R. Treatment with benidipine significantly decreased I/R-induced elevation of the 
plasma aldosterone concentration. I/R-induced markers of fibrosis in hearts also reduced in 
benidipine. These results suggest that the administration of benidipine reduces myocardial infarct 
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size as well as systemic oxidative stress after I/R. These phenomena are partially linked to 
reduced plasma aldosterone levels.   
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Introduction 
Early recanalization of an occluded coronary artery in acute myocardial infarction (MI) reduces 
the extent of myocardial necrosis, improves prognosis, and preserves the function of the left 
ventricle (LV).1 On the other hand, opening an occluded coronary artery can sometimes induce 
myocardial ischemia reperfusion (I/R) injury.2 A growing body of evidence demonstrates that 
reperfusion after ischemia results in additional cell death and enhances infarct size, called I/R 
injury.3 One major component of I/R injury mediating the development and progression of 
postischemic myocardial damage is oxidative stress, which leads to cardiomyocytes’ apoptosis.4 
It is important to block the rennin-angiotensin-aldosterone pathway after MI. Indeed, aldosterone 
might be essential to the pathophysiology of cardiovascular injury.5 Using a mineralocorticoid 
receptor (MR) antagonist in addition to standard therapy also appears to reduce clinical mortality, 
6 which suggests that MR activation may play a role in MI and heart failure. MR blockade is 
associated with decreased fibrosis, vascular inflammation, reduced oxidative stress, and I/R 
injury7 and endothelial dysfunction. 8 Accordingly, aldosterone must be an important risk factor 
for cardiovascular diseases. 
Benidipine, a long-acting dihydropyridine calcium channel blocker, is used widely to treat 
hypertension and ischemic heart disease.9-10 Benidipine evokes the vasodilatation of coronary and 
peripheral arteries by inhibiting calcium influx via L-type calcium channels. Benidipine also has 
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the effect to block T- and N-type calcium channels. This unique calcium channel blocker exhibits 
additional pharmacological effects, such as limiting infarct size via bradykinin and nitric 
oxide-dependent mechanisms in the canine heart,11 and reducing the production of hydroxyl 
radicals in rabbits.12 Benidipine also inhibits the production of aldosterone in human 
adrenocortical cells through the suppression of T-type calcium channels.13 However, it remains 
unknown whether this calcium channel blocker attenuates myocardial I/R injuries and 
aldosterone production in mice. 
In the current study, we demonstrated that benidipine would reduce myocardial infarction size 
following I/R in mice. We also showed that benidipine decreased I/R-induced oxidative stress 
through mechanisms partially involving down-regulation in plasma aldosterone concentration.  
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Methods 
An expanded Methods section is available in the Online Supplement. 
Experimental protocol 
The experiments were approved by the institutional and governmental animal research 
committees and were conducted in accordance with the Guide for the Care and Use of Laboratory 
Animals in Kanazawa University which strictly conforms to Guide for the Care and Use of 
Laboratory, published by the US National Institutes of Health (NIH Publication No. 85-23, 
revised 1996).  
Ischemia reperfusion and administration of drugs 
The method for inducing myocardial I/R in mice has been described.14 Male C57BL/6J mice 
(BW 24.5 ± 1.86 g, 8-12 weeks of age, Charles River Laboratories) were subjected to I/R or sham 
operation. Sham and I/R + V (vehicle) groups were orally administered 0.3% sodium 
carboxymethyl cellulose (CMC)15 by gavage daily from 7 days before the operation to 14 days 
after it. In the I/R + Beni groups, a 3 mg kg-1 dose of benidipine (Kyowa Kirin, Tokyo, Japan) 
dissolved by CMC was administered similarly and the same surgical procedures of I/R were 
followed. Nifedipine (3 mg kg-1) was orally administered daily from 7 days before operation in 
mice. Eplenerone (200 mg kg-1) was administered daily from just before operation of I/R to 7 
days after operation. In I/R + Beni + Aldo groups, mice received a continuous infusion of 
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aldosterone by micro pump at a dose of 8 μg kg-1 per day for 4 days. Previous reports 16-19 and 
preliminary experiments indicated that this dose of these drugs does not reduce blood pressure in 
C57BL/6J mice (Supplementary Table 1 and 2).  
Measurement of plasma aldosterone concentration (PAC), plasma renin activity (PRA) 
Then blood samples were collected from the left ventricular apex in before operation and 24 h, 2, 
4 and 7 days after operation, and PAC was measured by radioimmunoassay (Coat-a-count; 
DPC).20 PRA in 24 h after operation was measured by PRA kit (TFB, Japan). 21 
Hemodynamic measurements  
Systolic blood pressure, mean blood pressure, and heart rate were measured in unanesthetized 
mice using a computerized tail-cuff system22 (BP-98A system; Softron Co., Tokyo, Japan). The 
animals were placed in restraining units mounted on a warmed (36–37°C) surface (THC-2; 
Softron Co.), and their tails were passed through a cuff. Each session included more than 10 
tail-cuff measurements.   
Determination of myocardial apoptosis 
Myocardial apoptosis was determined by TdT-mediated dUTP nick end labeling (TUNEL) 
staining using an in situ apoptosis detection kit (Takara, Shiga, Japan) 24 h after operating. The 
positively stained nuclei were counted under 200 x magnifications and the ratio of positively 
stained apoptotic cells to all cells was evaluated. 
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Assessment of myocardial oxidative stress 
Myocardial oxidative stress was assessed by an immunohistochemical method using the mouse 
ImmunoCruz™ staining system (sc-2050; Santa Cruz Biotechnology, Inc. CA, USA) for 
8-hydroxy-2’-deoxyguanosine (8-OHdG)23 24 h after the operation.  
Urine collection and assessment of systemic oxidative stress 
The urine samples, collected using metabolic cages for mice (Shinano, Japan) in before operation 
and 24 h, 2, 4, 7 and 14 days after operation, were stored at –80C until use. We performed an 
enzyme-linked immunosorbent assay (ELISA) to detect urinary 8-OHdG using the New 8-OHdG 
Check ELISA Kit (Japan Institute for the Control of Aging, Shizuoka, Japan). 
Isolation of mRNA and quantitative real-time polymerase chain reaction (PCR) 
 Total RNA was isolated using RNeasy (Qiagen) from heart according to the protocol of the 
manufacturer. Total RNA (1g) was used to generate cDNA using Rever Tra Ace (Toyobo, Osaka, 
Japan) according to the protocol of the manufacturer. Real-time Quantitative PCR analysis was 
perfomed using the ABI PRISM 7300 sequence detection system (Applied Biosystems, Foster, 
CA). The following primers and TaqMan probes (Applied Biosystems) were used: interleukin 6 
(Il6 Mm99999064_m1), tumor necrosis factor (Tnf, ID# Mm00443258_m1), collagen, type I, 
alpha1 (Col1a1, ID# Mm00801666_g1), alpha smooth muscle actin (Acta2, ID# 
Mm01546133_m1), gp91phox (cybb, ID# Mm00432775_m1), p22phox (cyba, ID# 
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Mm00514478_m1), p47phox (ncf1, ID# Mm00447921_m1), p67phox(ncf2, ID# 
Mm00726636_s1), Mineralocorticoid receptor (MR) (nr3c2, ID# Mm01241596_m1). 
Glyceraldehyde-3-phsphate Dehydrogenase (Gapdh, ID# Mm99999915_g1) were used as an 
endogenous control.  
Statistical analysis 
The values, represented as the mean  standard error for each group of mice, were assessed by 
ANOVA with a subsequent Bonferroni’s post hoc test for multiple comparisons. The significance 
of differences between two groups was determined using the Student’s t test. Associations of 
urinary 8-OHdG and FS were assessed by Pearson correlation coefficient. Statistical significance 
was established at a value of p <0.05. All statistical analyses were performed using StatView 




Before the operation, the administration of benidipine did not affect heart rate, systolic/mean 
blood pressure, and urine volume (Table 1). The heart rate and urine volume did not differ 
significantly at each time point among the three groups throughout the protocol. In mice 
subjected to I/R, the systolic and mean blood pressures 2 and 4 days after operation were 
significantly lower than those of the sham groups, with or without benidipine. These results 
indicate that there were no significant changes in hemodynamic parameters during the oral 
administration of benidipine. 
Effect of benidipine on myocardial infarct size and left ventricular function after I/R 
To examine the effects of benidipine on cardioprotection during I/R injury, we applied 30 min of 
ischemia and a subsequent 24 h of reperfusion to I/R mice. The mean AAR in the left ventricular 
(LV) area was no different with or without benidipine (Figure 1B). I/R significantly increased 
IA/AAR after 24 h of reperfusion compared to the sham mice, but the administration of 
benidipine significantly attenuated I/R-induced increases in IA/AAR (Figures 1A, 1C). To 
examine the effect of L-type calcium channel blocker on I/R injury, nifedipine, a pure L-type 
calcium channel blocker, was administrated. The administration of nifedipine did not affect the 
heart rate and systolic and mean blood pressures after I/R. IA/AAR after 24 h of reperfusion was 
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similar in I/R+Nife compared to IR+V groups (Supplemental Figure 1). 
Echocardiographic measurements showed that I/R resulted in LV dilatation and decreased 
fractional shortening (%FS), compared to sham mice. The administration of benidipine 
significantly attenuated I/R-induced increases in LVEDD (Figure 1D) as well as decreases 
in %FS (2.69  0.07 versus 3.15  0.07 mm, p <0.01; 41.2  0.9 versus 33.3  0.8 %, p <0.01; 
respectively; Figure 1E). Taken together, these results suggest that benidipine, not nifedipine, 
attenuates I/R-induced myocardial infarct size and LV dysfunction. 
Benidipine attenuates apoptosis following I/R 
I/R injury is associated with increased apoptosis in the myocardium. To determine the extent of 
apoptosis, TUNEL-positive nuclei were counted among 5,000 nuclei in the AAR of each mouse. 
The number of TUNEL-positive myocytes was significantly higher in I/R+V groups than in sham 
mice (9.0 ± 0.9% versus 1.0 ± 0.3%, p <0.0001; Figures 2A and 2B), suggesting that apoptosis is 
enhanced during cardiac I/R. The number of TUNEL-positive myocytes was also induced in 
I/R+Beni groups, but I/R-induced TUNEL-positive myocyte was significantly lower than in 
I/R+V groups (6.0 ± 1.3% versus 9.0 ± 0.9%, p <0.05). Protein levels of total bax were increased 
and protein levels of bcl-2 were decreased in I/R+V groups (Figure 2C). I/R-induced changes of 
bax and bcl-2 were not observed in I/R+Beni groups. Furthermore, the level of eNOS 
phosphorylation was increased after I/R. I/R-induced eNOS phosphorylation was higher in 
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I/R+Beni than in I/R+V (Supplementary Figure 2). These results suggest that benidipine inhibits 
cardiac myocyte apoptosis induced by I/R. 
Myocardial oxidative stress after I/R 
To examine oxidative stress after I/R in hearts, we evaluated the myocardial levels of 8-OHdG, a 
sensitive indicator of oxidative DNA damage. As shown in Figure 3, I/R significantly increased 
8-OHdG expression in the AAR (12.4 ± 1.3% versus 2.7 ± 0.4%, p <0.0001). The administration 
of benidipine attenuated this response (6.7 ± 0.4% versus 12.4 ± 1.3%, p <0.05). The expression 
of gp91phox, NAD(P)H oxidase, mRNA was decreased in I/R+Beni compared to I/R+V 
(Supplementary Figure 3). These results suggest that benidipine attenuates cardiac oxidative 
stress after I/R. 
Aldosterone plasma levels after I/R 
Plasma aldosterone levels were markedly elevated after I/R, with a peak at 2 days that gradually 
declined thereafter but remained elevated for at least 7 days (Figure 4A). Plasma renin activities 
were significantly increased in both I/R+V and I/R+Beni groups compared to sham 
(Supplementary Table 3). Administration of benidipine in this model was not associated with an 
increase in serum renin activities. I/R was not affected the levels of serum potassium. 
Interestingly, the administration of benidipine significantly inhibited this response 2 and 4 days 
after I/R. The administration of nifedipine did not affect aldosterone levels after I/R (Figure 4B). 
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These results suggest that benidipine inhibits aldosterone production in response to I/R. 
Systemic oxidative stress and cardiac remodeling after I/R 
We estimated the ratio of urinary 8-OHdG to creatinine (Cr), a marker of systemic oxidative 
DNA damage induced by reactive oxygen species. Urinary 8-OHdG/Cr levels increased 
significantly in mice subjected to I/R compared to sham mice after operation (days 1, 2, 4, and 7). 
Benidipine significantly attenuated this response (Figure 5A), as did the administration of 
eplerenone, a selective mineral corticoid receptor antagonist (Figure 5B). Furthermore, 
continuous infusion of aldosterone abolished the benidipine’s inhibition of I/R induced urinary 
8-OHdG/Cr levels. These results suggest that benidipine attenuates cardiac and systemic 
oxidative stress after I/R through aldosterone production. We also examined the effect of 
benidipine administration for cardiac inflammation and remodeling after I/R. We isolated heart 
tissues 4 days after I/R for quantitative real-time PCR. The mRNA expression level of 
mineralocorticoid receptor (MR) was no changes in both I/R+V and I/R+Beni compared to sham 
groups (Supplementary Figure 4). Multiple markers of inflammation and fibrotic remodeling 
were elevated in I/R compared to sham. I/R-induced mRNA upregulations of IL6, TNF, Col1a1 
and Acta2 were decreased in I/R+Beni groups (Figure 5C, 5D, 5E and 5F). In aldosterone 
infusion mice, mRNA upregulations of only Colla1 was significantly elevated. Continuous 
infusion of aldosterone partially reduced the beneficial effect of benidipine. These results indicate 
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that administration of benidipine inhibited I/R-induced cardiac inflammation and fibrotic 
remodeling, partially through the production of aldosterone.  
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Discussion 
In this study, the long-acting dihydropyridine calcium channel blocker benidipine, when 
administered at a dose that did not decrease blood pressure, reduced the myocardial infarct size, 
apoptosis of cardiac myocytes, and myocardial 8-OHdG in I/R. These results suggest that the 
cardioprotective effects of benidipine may be independent of its anti-hypertensive effects.  
This study demonstrated the following major findings. First, benidipine reduces infarct size and 
may be improve cardiac dysfunction following I/R. Second, benidipine reduces the plasma 
aldosterone concentration that increases due to I/R. Finally, benidipine inhibits I/R-induced 
increases in urinary 8-OHdG and cardiac inflammatory responses and fibrotic remodeling. Thus, 
these results suggest that benidipine may be a useful cardioprotective agent against oxidative 
stress and could potentially serve as a therapeutic strategy for I/R injury. 
It was previously demonstrated that benidipine limits I/R injury in vivo. In canine ischemia 
reperfused hearts, benidipine increased the nitric oxide (NO) and bradykinin (BK) levels of 
coronary venous blood and limited infarct size.11 Wang et al. reported that benidipine reduced 
myocardial infarct size by reducing hydroxyl radicals and inducing the production of NO in 
rabbits.12 Moreover, benidipine has been shown to reduce postischemic myocardial apoptosis by 
inhibiting caspase-3 activation.24 In the current study, we demonstrated that the oral 
administration of benidipine reduces myocardial infarct size. Expression of bax protein was 
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increased and bcl2 protein was decreased in hearts after I/R. These changes in apoptotic 
regulating proteins did not occur by administration of benidipine. Consequently, the number of 
TUNEL positive cells was smaller in benidipine treatment. We also demonstrated that benidipine 
increased eNOS activity in hearts. Based on our results, we suggest that the reduction of hydroxyl 
radicals may play one of the important key roles in the cardioprotective effect of benidipine. 
Benidipine treatment (3 mg kg-1 per day) did not affect to blood pressure and heart rate. Even 
after I/R, these parameters showed no difference with or without benidipine. Consistent with 
previous work,16 these results suggest that the cardioprotective effect of benidipine is likely to be 
independent of blood pressure, because the dose of benidipine used in this study did not 
significantly affect systemic blood pressure.  
The generation of free radicals and oxidants is associated with the exacerbation of reperfusion 
injury in myocardial I/R.25 8-OHdG is a sensitive and integral marker of oxidative damage to 
DNA. Cordis et al. reported that 8-OHdG is formed at the onset of reperfusion in the 
myocardium.26 Benidipine treatment reduces the level of hydroxyl radicals in reperfused 
myocardium in rabbit.11 In the current study, 8-OHdG accumulated in mouse hearts 24 h after 
reperfusion, but benidipine treatment reduced 8-OHdG levels. Benidipine also suppressed 
increases of gp91phox, one of the important components of NAD(P)H oxidase, after I/R. In 
addition, urinary 8-OHdG, a marker of systemic oxidative stress, was elevated in both the early (1 
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and 2 days after reperfusion) and late phases (4 and 7 days after reperfusion), and benidipine 
reduced urinary 8-OHdG levels in both phases. We suggests that reduction of myocardial 
oxidative stress is one of the mechanism through which benidipine decreases infarct size, and that 
myocardial oxidative stress reflect systemic oxidative stress in the early phase after reperfusion. 
Aldosterone, an antidiuretic hormone, plays an important role in regulating electrolyte 
composition by promoting sodium retention and potassium excretion27 and MR antagonist 
regressed hypertrophy, fibrosis and diastolic dysfunction in human and experimental hypertensive 
heart disease28-29.  Excess of mineralocorticoid causes cardiac hypertrophy, fibrosis and diastolic 
dysfunction30-31. In the current study, we found for the first time that the plasma concentration of 
aldosterone increased after I/R partially through the upregulation of plasma rennin activity and 
benidipine treatment effectively inhibited this response in vivo. Aldosterone is produced mainly 
by the adrenal cortex in response to increased potassium or angiotensin II.32 Benidipine inhibits 
angiotensin II-induced aldosterone production by regulating T-type calcium channels.13 The 
synthesis of aldosterone requires the aldosterone synthetase CYP11B2.33 Several reports has been 
shown that there are CYP11B2 mRNA expressions and activities in hearts and vessel walls,34 
however, results regarding the synthesis of aldosterone in the heart and peripheral vasculature are 
contradictory.35 We tried to examine the mRNA expression levels of CYP11B2 in the heart, aorta, 
and kidney using quantitative real-time PCR, but we could not detect the expression of CYP11B2 
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in any tissues (data not shown). Furthermore, we found that the administration of nifedipine, a 
pure L-type calcium channel blocker, did not inhibit I/R-induced aldosterone production. Based 
on these results, we speculate that benidipine inhibits aldosterone synthesis in the adrenal gland 
by blocking T-type calcium channels. At present, however, this hypothesis remains to be tested. 
Oxidative stress and inflammation lead to increased cardiovascular morbidity and mortality.36 
Much evidence indicates that aldosterone and/or MR activation result in oxidative stress and 
vascular inflammation. Aldosterone itself enhances NAD(P)H oxidase activation,37 a major 
source of reactive oxygen species, and the MR blocker inhibits angiotensin II-induced activation 
of NAD(P)H oxidase activity and myocardial interstitial fibrosis after MI. This study 
demonstrates the I/R-induced enhancement of urinary 8-OHdG in the late phase and elevation of 
PAC. Interestingly, the elevation in urinary 8-OHdG was reduced by both benidipine and 
eplerenone in the late phase after reperfusion. Continuous infusion of aldosterone was abolished 
beneficial effects of benidipine after I/R. These results suggest that MR regulates I/R-induced 
increases in 8-OHdG. Benidipine also reduced I/R-induced inflammatory and fibrotic responses 
in hearts. These effects partially canceled by continuous infusion of aldosterone. In addition, 
benidipine also appears to have renoprotective and vascular endothelial protective effects38. 
These results further suggest that the inhibition of aldosterone production and oxidative stresses 
contributes to the cardioprotective effect of benidipine and that benidipine provides a beneficial 
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effect to multiple organs following cardiac I/R.  
In conclusions benidipine, calcium channel blocker, reduces I/R injury by inhibiting cardiac 
myocyte apoptosis, aldosterone production, oxidative stress, and inflammation in mice. Our 
results suggest that benidipine, as a T-type calcium channel blocker, has additional benefits for 
cardiovascular disease beyond its anti-hypertensive effects. Thus benidipine will be able to 
potentially serve as a therapeutic strategy for I/R injury.  
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Figure 1. (A) Representative examples of myocardial infarction stained with Evans blue 
(EB)/triphenyl tetrazolium chloride (TTC) 24 h after ischemia reperfusion. Benidipine decreases 
infarct size. EB-stained areas (purple staining) indicate nonischemic regions; TTC-stained areas 
(red staining) indicate ischemic but viable tissue; EB/TTC stained negative (white) areas indicate 
myocardium infarcts. (B) Area at risk (AAR) and infarct area (IA) of the I/R + V and I/R + Beni 
groups. There was no significant difference in the AAR between the two groups. Infarct size was 
significantly reduced in the I/R + Beni group compared to that of the I/R + V group (C). LV, left 
ventricular area. N = 4 per group. Data are expressed as mean ± SEM. (D), (E) Effect of 
benidipine on myocardial function 7 days after ischemic reperfusion as determined by 
echocardiography. LVEDD, left ventricular end-diastolic diameter; FS, fractional shortening. N = 
10 per group. Data are expressed as mean ± SEM.  
 
Figure 2. (A) Representative examples of myocardial apoptotic cells by TdT-mediated dUTP 
nick end labeling (TUNEL) staining of the area at risk (AAR) 24 h after operation. There were 
fewer TUNEL-positive cells (dark brown) in the I/R + Beni group than in the I/R + V group. 
There was a significant difference in the TUNEL-positive cells among the three groups (B). 
Myocardial apoptosis was significantly lower in the I/R + Beni group than the I/R + V group. (C) 
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Immunoblots with anti-bax and anti-bcl2 antibodies are shown. N = 6–7 per group. Data are 
expressed as mean ± SEM. 
 
Figure 3. (A) Representative examples of myocardial 8-hydroxydeoxyguanosine (8-OHdG) 
staining by an immunohistochemical method at the area at risk (AAR) 24 h after operation. There 
were fewer 8-OHdG-positive cells (brown) in the I/R + Beni group than in the I/R + V group. 
There was a significant difference in the number of 8-OHdG-positive cells among the three 
groups (B). N = 5 per group. Data are expressed as mean ± SEM. 
 
Figure 4. (A) Effect of benidipine on plasma aldosterone concentration (PAC), from before I/R to 
7 days after I/R (N = 5 per group). (B) PAC in the I/R group that was administered nifedipine (3 
mg/kg/day from 7 days before) compared to three other groups on day 2. Nifedipine did not 
significantly inhibit the elevation of PAC-induced I/R (N = 5). Data are expressed as mean ± 
SEM. §P <0.05 versus sham group, †p <0.05 versus I/R + V group. 
 
Figure 5. (A) Effect of benidipine on systemic oxidative stress before I/R to 14 days after I/R as 
determined by urinary 8-OHdG/Cr levels (n = 9–10 per group). §P <0.05 versus the sham group, 
§§p <0.05 versus sham group, †p <0.05 versus I/R + V group, ††p <0.01 versus I/R + V group. (B) 
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The urinary 8-OHdG/Cr level on day 4. Eplerenone significantly inhibited the elevation of 
I/R-induced urinary 8-OHdG/Cr levels (n = 10). Continuous infusion of aldosterone canceled the 
suppression of benidipine in I/R-induced urinary 8-OHdG/Cr levels. Inflammatory cytokines and 
fibrotic markers expression. Myocardial mRNA levels of IL6 (C), TNF (D), Collagen Ia (E), 



















































































































































































































































































P < 0.01 P < 0.05 P < 0.05 P < 0.05


































































Supplementary Figure 1. 
Area at risk (AAR) and infarct area (IA) of the I/R+V, I/R+Beni and I/R+Nife groups. 
(A) There was no significant difference in the AAR among three groups. 
(B) Infarct size was significantly reduced in the I/R+Beni compared to that of the I/R+V and 
I/R+Nife groups. Data are expressed as mean ± SEM
p-eNOS





Supplementary Figure 2. 
Benidipine reduced I/R-induced phosphorylation of eNOS in hearts.
Immunoblot analysis of phosphorylated eNOS are shown. 




























































Supplementary Figure 3. 
mRNA expression of NAD(P)H oxidase was determined by Taqman RT-PCR. A, p22phox; 
B, gp91phox; C, p47phox; D, p67phox. Data are expressed as mean ± SEM














Supplementary Figure 4. 
mRNA expression of mineralocorticoid receptor (MR) was determined by Taqman RT-PCR. 
Data are expressed as mean ± SEM













Systolic blood pressure (mmHg)

















Values are expressed as mean ± SEM (N=9 to 10/group)
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Values are expressed as mean ± SEM (N=9 to 10/group)














Values are expressed as mean ± SEM (N=6 to 8/group)










Supplementary Table 3. 
Serum potassium levels and plasma renin activity after I/R
